Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out the advertisement of prescriptions for injectable weight-loss drugs without ...

Hims & Hers faced backlash over its Super Bowl ad touting its compound weight loss drug while slamming pharmaceutical giants ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

Aptar has a narrow economic moat, with durable switching costs in the Pharma business supported by intangible assets throughout the product portfolio from expertise in product regulation, design, and ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

The spot makes lofty claims about weight-loss drugs offered by the telehealth company Hims & Hers, but says little about ...

Genevieve Roberts thought weight-loss drugs were a miracle – until excruciating side-effects sent her straight back to a ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.